SCHEMBL948580

SCHEMBL948580

c1ccn2c(-c3ccncc3)ncc2c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.77
ALDH1A1 P00352 10/20 0.77
MAPT P10636 6/20 0.77
LIMK1 P53667 2/20 0.77
MAPK14 Q16539 2/20 0.77
CHEK1 O14757 1/20 0.77
TDP1 Q9NUW8 1/20 0.77
MEN1 O00255 5/20 0.68
KMT2A Q03164 5/20 0.68
RAB9A P51151 5/20 0.68
MAPK1 P28482 2/20 0.68
NPC1 O15118 2/20 0.68
HPGD P15428 6/20 0.62
HSD17B10 Q99714 3/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
POLB P06746 1/20 0.57
BACE1 P56817 1/20 0.45
ALOX5 P09917 1/20 0.44
GLA P06280 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11534549 0.87 KDM4E (1.00) KDM4EALDH1A1MAPTLIMK1MAPK14
SCHEMBL13325866 0.82 ALDH1A1 (0.77) KDM4EALDH1A1MAPTLIMK1MAPK14
SCHEMBL13325867 0.81 MEN1 (1.00) KDM4EALDH1A1MAPTLIMK1MAPK14
SCHEMBL31215225 0.80 MEN1 (0.69) KDM4EALDH1A1MAPTLIMK1MAPK14
SCHEMBL16796325 0.78 KDM4E (0.65) KDM4EALDH1A1MAPTLIMK1MAPK14
SCHEMBL13325865 0.77 KDM4E (1.00) KDM4EALDH1A1MAPTLIMK1MAPK14
SCHEMBL13325871 0.75 KDM4E (0.61) KDM4EALDH1A1MAPTLIMK1MAPK14
SCHEMBL10095082 0.75 KDM4E (0.66) KDM4EALDH1A1MAPTLIMK1MAPK14
SCHEMBL13325870 0.75 KDM4E (0.65) KDM4EALDH1A1MAPTLIMK1MAPK14
SCHEMBL4917654 0.72 ALDH1A1 (0.49) KDM4EALDH1A1MAPTLIMK1MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2903978-B1 GDF-8 INHIBITORS RIGEL PHARMACEUTICALS INC (US) 2022-12-07 EP claimed
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-13 US disclosed
US-20070004736-A1 Imidazole derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-04 US disclosed
EP-1564213-A1 IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004736-A1 Imidazole derivative, process for producing the same, and use HRH4, F2, HRH2 KDM4E 1356/4885ALDH1A1 2246/4885MAPT 4771/4885
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE F2, H1-3, CYC1 KDM4E 1558/4885ALDH1A1 2316/4885MAPT 4800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.